The chemosensitivity of dMMR/MSI‐high gastric cancer was also explored in KEYNOTE‐062, which investigated the superiority of chemotherapy plus pembrolizumab and the non‐inferiority of pembrolizumab monotherapy over conventional chemotherapy in patients with unresectable/recurrent gastric cancer with a programmed cell death ligand 1 (PD‐L1) combined positive score (CPS) of 1 or greater.36 The gene discussed is CD274; the disease is gastric cancer.